YWP
PTCT icon

YorkBridge Wealth Partners’s PTC Therapeutics PTCT Stock Holding History

YorkBridge Wealth Partners’s Portfolio PTCT Stock Details PTCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-6,000
Closed -$74K – 908
2016
Q4 		$74K Buy
+6,000
New +$62.9K 0.04% 292

Other funds holding PTCT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
JGC
J. Goldman & Co New York $3.44B AUM 33.8% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

YorkBridge Wealth Partners's PTCT Position: Q1 2017 in Review

YorkBridge Wealth Partners sold out of PTC Therapeutics (PTCT) in Q1 2017, closing a stake of 6,000 shares — an estimated $74K sold.

YorkBridge Wealth Partners first reported a position in PTCT in Q4 2016 and held it in 1 quarter. The position peaked at $74K in Q4 2016. 115 funds tracked by Wall St. Rank hold PTCT as of Q1 2017.

  • YorkBridge Wealth Partners reported no remaining PTC Therapeutics position as of Q1 2017 after selling out during the quarter.
  • YorkBridge Wealth Partners sold 6,000 PTC Therapeutics shares in Q1 2017, an estimated $74K.
  • YorkBridge Wealth Partners first reported a position in PTC Therapeutics in Q4 2016 and held it in 1 quarter.
  • YorkBridge Wealth Partners's PTC Therapeutics position peaked at $74K in Q4 2016.
  • 115 funds tracked by Wall St. Rank held PTC Therapeutics as of Q1 2017.

Based on YorkBridge Wealth Partners's 13F filing for Q1 2017, filed 5 May 2017.